Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
暂无分享,去创建一个
R. Morgan | L. Couture | C. Mullen | J. Ragheb | A. Ridgway
[1] R. Morgan,et al. Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. , 2000, Human gene therapy.
[2] R. Morgan,et al. Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. , 2000, Human gene therapy.
[3] Richard A. Morgan,et al. Gene Therapy for Infectious Diseases , 1998, Clinical Microbiology Reviews.
[4] M A Nowak,et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[6] D. Littman,et al. Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene , 1997, Journal of virology.
[7] S. Matsushita,et al. Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. , 1996, Human gene therapy.
[8] R. Morgan,et al. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. , 1996, Human gene therapy.
[9] G. Nabel,et al. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[10] C. Mullen,et al. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. , 1996, Cancer research.
[11] P. Narciso,et al. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. , 1996, AIDS research and human retroviruses.
[12] M. Daucher,et al. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. , 1995, AIDS research and human retroviruses.
[13] T. Curiel,et al. HIV-regulated diphtheria toxin A chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line U937. , 1995, Human gene therapy.
[14] R. Morgan,et al. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes , 1995, Journal of virology.
[15] B. Jacobsson,et al. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. , 1995, AIDS research and human retroviruses.
[16] I. Lowy,et al. Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. , 1995, Virology.
[17] P. Pitha,et al. Inhibition of human immunodeficiency virus type 1 replication by a Tat-activated, transduced interferon gene: targeted expression to human immunodeficiency virus type 1-infected cells , 1995, Journal of virology.
[18] R. Morgan,et al. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. , 1994, Human gene therapy.
[19] M J Sheehy,et al. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[20] W. Anderson,et al. Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1. , 1994, AIDS research and human retroviruses.
[21] R. Blaese,et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. , 1994, Cancer research.
[22] D. Pennington,et al. Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[23] S. Ghosh,et al. Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-regulated diphtheria toxin A chain gene. , 1993, Human gene therapy.
[24] J. Lisziewicz,et al. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Daucher,et al. Factors affecting retroviral vector function and structural integrity. , 1993, Virology.
[26] O. Yamada,et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[27] C. Zhou,et al. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes , 1993, Journal of virology.
[28] J. Ojwang,et al. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[29] M. Malim,et al. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication , 1992, The Journal of experimental medicine.
[30] T. Curiel,et al. Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. , 1992, Human gene therapy.
[31] M. Feinberg,et al. Intracellular immunization: trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication. , 1992, AIDS research and human retroviruses.
[32] A. Panganiban,et al. Human immunodeficiency virus vectors for inducible expression of foreign genes , 1992, Journal of virology.
[33] B. Sullenger,et al. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation , 1991, Journal of virology.
[34] S. Read,et al. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme , 1991, Journal of virology.
[35] S. Astrin,et al. Human immunodeficiency virus induction of malignant transformation in human B lymphocytes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[36] E. Vivés,et al. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1 , 1991 .
[37] S. Salahuddin,et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.
[38] A. Nienhuis,et al. Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[39] B. Berkhout,et al. Tat trans-activates the human immunodeficiency virus through a nascent RNA target , 1989, Cell.
[40] M. Mathews,et al. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation , 1989, Cell.
[41] D. Baltimore,et al. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus , 1989, Cell.
[42] D. Bednarik,et al. Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[43] M. Malim,et al. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes , 1988, Nature.
[44] J. Ghrayeb,et al. Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis. , 1987, Science.
[45] M. Bender,et al. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region , 1987, Journal of virology.
[46] D. Capon,et al. Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein , 1987, Cell.
[47] M. Feinberg,et al. HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA , 1986, Cell.
[48] J. Sodroski,et al. A second post-transcriptional trans-activator gene required for HTLV-III replication , 1986, Nature.
[49] V. Avramis,et al. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. , 1995, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.
[50] G. Th. The International Retrovirology Association Starts a New Venture with JAIDS & HR of Raven Press , 1995 .
[51] B. Fox,et al. A molecular genetic intervention for AIDS--effects of a transdominant negative form of Rev. , 1994, Human gene therapy.
[52] D. Klatzmann,et al. Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. , 1992, Proceedings of the National Academy of Sciences of the United States of America.